1 day Ago By Defense World Staff
Arrowstreet Capital Limited Partnership bought a new position in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 30,504 shares of the company’s stock, valued at approximately $784,000. Other large investors have also recently bought and sold shares of the company.
Geode Capital Management LLC increased its stake in shares of NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after buying an additional 1,399 shares during the period.
Mirae Asset Global Investments Co. Ltd. bought a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $80,000.
KLP Kapitalforvaltning AS acquired a new position in NewAmsterdam Pharma in the 4th quarter valued at approximately $154,000. Barclays PLC raised its stake in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter.
Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after acquiring an additional 7,199 shares during the last quarter. Finally, HB Wealth Management LLC bought a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth $224,000. 89.
89% of the stock is currently owned by institutional investors. Insider ActivityIn related news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.
37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550.
This trade represents a 90.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Also, Director James N. Topper purchased 4,005 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were acquired at an average price of $21.
02 per share, with a total value of $84,185.10. Following the purchase, the director now directly owns 3,012,434 shares in the company, valued at $63,321,362.
68. This represents a 0.13 % increase in their position.
The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh InA number of analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th.
Royal Bank of Canada restated an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Scotiabank lifted their price objective on NewAmsterdam Pharma from $47.
00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Thursday, February 27th. UBS Group set a $41.
00 target price on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $42.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, April 8th.
Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $43.33.View Our Latest Stock Analysis on NewAmsterdam PharmaNewAmsterdam Pharma Stock PerformanceShares of NAMS stock opened at $15.
12 on Friday. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $27.
29. The stock has a 50 day simple moving average of $20.26 and a two-hundred day simple moving average of $21.
26. The company has a market cap of $1.66 billion, a P/E ratio of -5.
82 and a beta of -0.01. NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last released its earnings results on Wednesday, February 26th.
The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.
47). The company had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.
30 million. On average, research analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.
About NewAmsterdam Pharma (Free Report)NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.Read MoreFive stocks we like better than NewAmsterdam PharmaWhat is a Special Dividend?Robinhood Strategies Could Be a Game-Changer for Young InvestorsA Deeper Look at Bid-Ask SpreadsAre These 3 Retail Stocks Oversold or Really in Trouble?How to Use the MarketBeat Stock Screener IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead.
